Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.42 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.40 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.40 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.40 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9506889 | 1.00 | LPAR5 (0.52) | LPAR5HTTUSP2PLA2G2CCYP1A2 | |
| SCHEMBL9508410 | 0.90 | PLA2G2D (0.46) | LPAR5HTTPLA2G2CLPAR3LPAR1 | |
| SCHEMBL5180047 | 0.86 | USP2 (0.53) | LPAR5HTTUSP2PLA2G2CCYP1A2 | |
| SCHEMBL5604280 | 0.86 | USP2 (0.53) | LPAR5HTTUSP2PLA2G2CCYP1A2 | |
| SCHEMBL10601287 | 0.86 | USP2 (0.53) | LPAR5HTTUSP2PLA2G2CCYP1A2 | |
| SCHEMBL2497008 | 0.86 | USP2 (0.53) | LPAR5HTTUSP2PLA2G2CCYP1A2 | |
| SCHEMBL5180698 | 0.86 | USP2 (0.53) | LPAR5HTTUSP2PLA2G2CCYP1A2 | |
| SCHEMBL9417254 | 0.86 | USP2 (0.53) | LPAR5HTTUSP2PLA2G2CCYP1A2 | |
| SCHEMBL8536163 | 0.86 | USP2 (0.53) | LPAR5HTTUSP2PLA2G2CCYP1A2 | |
| SCHEMBL5179103 | 0.86 | USP2 (0.53) | LPAR5HTTUSP2PLA2G2CCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534213-B1 | WATER-BASED DELIVERY SYSTEMS | SKOELD THOMAS (SE) | 2013-04-24 | — | — | EP | claimed |
| JP-4806519-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| US-20090226491-A1 | Water-based delivery systems | SKOLD, THOMAS (SE) | 2009-09-10 | — | — | US | claimed |
| US-20090081139-A1 | Water-based delivery systems | GALDERMA LABORATORIES, INC. | 2009-03-26 | — | — | US | claimed |
| WO-2006039667-A2 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | claimed |
| EP-1534213-A4 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARM INC (US) | 2005-10-26 | — | — | EP | claimed |
| US-20050129722-A1 | For an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor; topical drug delivery | COLLAGENEX PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| EP-1534213-A2 | WATER-BASED DELIVERY SYSTEMS | Collagenex Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040009213-A1 | Water-based delivery systems | COLLAGENEX PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| WO-2003077861-A2 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARMACEUTICALS, INC. (US) | 2003-09-25 | — | — | WO | claimed |
| EP-1534213-B1 | WATER-BASED DELIVERY SYSTEMS | SKOELD THOMAS (SE) | 2013-04-24 | — | — | EP | disclosed |
| US-20090226491-A1 | Water-based delivery systems | SKOLD, THOMAS (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090081139-A1 | Water-based delivery systems | GALDERMA LABORATORIES, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2006039667-A2 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-1534213-A4 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARM INC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-5582832-A | CONTAINS AN AZOLE IN COMBINATION WITH A LIPID INGREDIENT; APPLYING TO IMPROVE OR PREVENT THE APPEARANCE OF WRINKLED, FLAKY, AGED OR PHOTODAMAGED SKIN | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0711558-A1 | Compositions for topical application to skin, hair and nails | UNILEVER PLC (GB) | 1996-05-15 | — | — | EP | disclosed |
| US-5476661-A | Mixture of 25-hydroxycholecalciferol, a ceramide lipid, and a carrier; keratinocyte prodifferentiation, cosmetics | ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) | 1995-12-19 | — | — | US | disclosed |
| EP-0555250-A1 | COSMETIC COMPOSITION | UNILEVER PLC (GB) | 1993-08-18 | — | — | EP | disclosed |
| WO-1992006982-A1 | COSMETIC COMPOSITION | UNILEVER PLC (GB) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050129722-A1 | For an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor; topical drug delivery | CERT1, CERS2, SGMS1 | LPAR5 324/4885HTT 4873/4885USP2 2769/4885 |
| US-20090226491-A1 | Water-based delivery systems | CERS2, SGMS2, SGMS1 | LPAR5 428/4885HTT 4752/4885USP2 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.